Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M8891 in Advanced Solid Tumors and Metastatic Renal Cell Carcinoma
NCT03138538Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Aug 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of m8891 in solid tumor (advanced stage) and metastatic renal cell carcinoma (mRCC), sponsored by EMD Serono. Started Aug 2017; status: terminated.
02
Drugs
m8891
03
Conditions
solid tumor (advanced stage)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03138538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138538.